Compare MDV & ELTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MDV | ELTX |
|---|---|---|
| Founded | 2015 | 2011 |
| Country | United States | United States |
| Employees | N/A | 26 |
| Industry | Transportation Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 147.9M | 134.1M |
| IPO Year | 2022 | N/A |
| Metric | MDV | ELTX |
|---|---|---|
| Price | $14.53 | $8.04 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $13.00 |
| AVG Volume (30 Days) | 35.5K | ★ 93.4K |
| Earning Date | 03-03-2026 | 11-13-2025 |
| Dividend Yield | ★ 8.07% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $47,479,000.00 | N/A |
| Revenue This Year | $0.13 | N/A |
| Revenue Next Year | $0.71 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $13.62 | $4.60 |
| 52 Week High | $17.15 | $12.62 |
| Indicator | MDV | ELTX |
|---|---|---|
| Relative Strength Index (RSI) | 52.90 | 49.78 |
| Support Level | $14.21 | $7.48 |
| Resistance Level | $14.50 | $8.59 |
| Average True Range (ATR) | 0.28 | 0.40 |
| MACD | 0.01 | 0.03 |
| Stochastic Oscillator | 70.86 | 57.70 |
Modiv Industrial Inc is a pioneer in the direct-to-consumer commercial real estate product industry. It provides individual investors access to real estate and real estate-related investments designed to provide both income and long-term growth. The Company has invested in single-tenant income-producing properties. Its current business consists of owning, managing, operating, leasing, acquiring, investing in and disposing of commercial real estate assets utilized for industrial manufacturing, as well as a few non-core assets. All of the company's consolidated revenues are derived from company's consolidated real estate properties.
Elicio Therapeutics Inc is a clinical-stage biotechnology company pioneering the development of cancer immunotherapies for patients with limited treatment options and poor outcomes. Its proprietary Amphiphile, or AMP, platform delivers investigational immunotherapeutics directly to the brain center of the immune system the lymph nodes. Its focus is the development of cancer immunotherapies against biologically validated but hard-to-drug targets that can be activated through lymph node trafficking.